What insurance policy changes affect code G93.89?

There are 4 tracked policy changes affecting code G93.89, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code G93.89?

Payers that have issued tracked updates for code G93.89 include: Aetna.

How do I get notified when code G93.89 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code G93.89. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code G93.89?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

G93.89 Insurance Policy Changes

ICD-10 G93.89 is officially defined as "Other specified disorders of brain." code G93.89 is referenced in 4 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code G93.89 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Aug 16, 2026Medium impact
Grid Monitoring and Intraoperative Electroencephalography (CPB 0289, reviewed 2026-04-17)
Aetna considers intraoperative scalp EEG medically necessary for monitoring cerebral function during carotid artery surgery, during intracranial vascular surgical procedures, and during parietal tumor resection or resection of a lesion near the eloquent cortex. Grid monitoring (electrocorticography) to determine the location of the epileptogenic focus for possible surgical resection is medically necessary for members with intractable seizures when seizures arise from functionally important brain areas, when surface EEG did not adequately localize the epileptogenic area, or when electrophysiological localization is discordant with other neurodiagnostic studies suggesting an abnormality in more than one region of the brain. EEG monitoring during WADA testing is medically necessary, while intraoperative EEG for open-heart surgery and grid monitoring for all other indications not listed are experimental, investigational, or unproven.
Aetna · Identified Aug 13, 2026Medium impact
Donanemab-azbt (Kisunla) (CPB 1066, reviewed 2025-10-17)
Aetna considers Kisunla (donanemab-azbt) medically necessary for Alzheimer's disease when the member is 50 or older, or is younger with an APP, PSEN1 or PSEN2 mutation or other documentation of early onset AD, is in Clinical Stage 3 or 4, has objective cognitive impairment, and has amyloid pathology confirmed by PET or by cerebrospinal fluid results. The initial criteria also require a brain MRI within one year before treatment, ApoE e4 genotype testing, a baseline CDR-GS of 0.5 or 1, MMSE of 21 to 30, or MoCA of 16 or greater within 12 months of treatment initiation, and participation in a provider-enrolled registry such as ALZ-NET. Anticoagulants may not be used with the drug, any antiplatelet agent must be used as monotherapy at a standard therapeutic dose, and precertification is required.
Aetna · Identified Oct 21, 2026Low impact
Thermal Perfusion Probe for Monitoring Regional Cerebral Blood Flow (CPB 0703, reviewed 2026-10-15)
Aetna's clinical policy bulletin 0703 treats thermal perfusion probes, which continuously measure regional cerebral blood flow after head injury, subarachnoid hemorrhage or neurosurgery, as experimental, investigational or unproven. It lists the diagnosis codes for neurological and cerebrovascular conditions that are not covered for this use, along with related CPT 0042T. The source is dated October 15, 2026 and states no effective date for a change, so treat it as reference criteria to confirm against Aetna's current version.
Aetna · Identified Aug 18, 2026Low impact
Thermal Perfusion Probe for Monitoring Regional Cerebral Blood Flow (CPB 0703, reviewed 2025-11-24)
This is a historical copy of Aetna's clinical policy on thermal perfusion probes for monitoring regional cerebral blood flow (CPB 0703), last reviewed November 24, 2025 and first found by PolicyChanges in August 2026. Aetna treats the probe as experimental, investigational or unproven for acute neurological conditions, and the source gives no effective date.

Watch G93.89

Get one email when a payer policy names G93.89, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Grid Monitoring and Intraoperative Electroencephalography (CPB 0289, reviewed 2026-04-17)

Donanemab-azbt (Kisunla) (CPB 1066, reviewed 2025-10-17)

Thermal Perfusion Probe for Monitoring Regional Cerebral Blood Flow (CPB 0703, reviewed 2026-10-15)

Thermal Perfusion Probe for Monitoring Regional Cerebral Blood Flow (CPB 0703, reviewed 2025-11-24)

What insurance policy changes affect code G93.89?

Which payers have updated policy for code G93.89?

How do I get notified when code G93.89 policy changes?

Why do payers change policies for code G93.89?